Literature DB >> 2895070

Effect of a kinin antagonist on the acute antihypertensive activity of enalaprilat in severe hypertension.

L F Carbonell1, O A Carretero, J M Stewart, A G Scicli.   

Abstract

The purpose of this study was to assess the role of kinins in the acute antihypertensive effect of the converting enzyme inhibitor (CEI) enalaprilat in rats with severe hypertension induced by aortic ligation between both renal arteries. For this study, we used a bradykinin analogue, D-Arg-Arg-Pro-Hyp-Gly-Thi-Ser-DPhe-Thi-Arg-TFA, with in vivo antagonistic properties. Hypertensive rats were infused intra-aortically for 15 minutes with either saline (30 microliters/min) or the kinin antagonist (40 micrograms/kg/min). Five minutes after the infusion was begun, a bolus injection of enalaprilat (60 micrograms/kg) was given. The blood pressure of the saline-infused animals decreased 48 +/- 6 mm Hg (from 180 +/- 7 to 132 +/- 7 mm Hg), while that of the rats treated with the antagonist decreased only 21 +/- 4 mm Hg (from 175 +/- 3 to 154 +/- 3 mm Hg). The difference between both decrements was significant (p less than 0.01). In another group of hypertensive animals (n = 9), we measured kinin concentration in plasma from arterial blood before and after administration of CEI (41 +/- 10 vs 68 +/- 20 pg/ml, respectively; NS). These results are consistent with the hypothesis that kinins play a role in the acute antihypertensive effect of CEIs in rats with severe hypertension. However, since arterial blood kinin concentrations were not increased significantly after CEI administration, the effect of the CEI may be due to an increase in tissue kinins, which could act as autacoids regulating vascular resistance.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2895070     DOI: 10.1161/01.hyp.11.3.239

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  13 in total

Review 1.  Control of coronary blood flow by autacoids.

Authors:  E Bassenge
Journal:  Basic Res Cardiol       Date:  1995 Mar-Apr       Impact factor: 17.165

Review 2.  The role of kinins in the antihypertensive and cardioprotective effects of ACE inhibitors.

Authors:  G Bönner
Journal:  Drugs       Date:  1997       Impact factor: 9.546

3.  The role of endogenous bradykinin in blood pressure homeostasis in spontaneously hypertensive rats.

Authors:  H R Holte; A Bjørnstad-Ostensen; T Berg
Journal:  Br J Pharmacol       Date:  1996-08       Impact factor: 8.739

Review 4.  Renal effects of antihypertensive drugs.

Authors:  W A Schlueter; D C Batlle
Journal:  Drugs       Date:  1989-06       Impact factor: 9.546

5.  Cyclic AMP selectively enhances bradykinin receptor synthesis and expression in cultured arterial smooth muscle. Inhibition of angiotensin II and vasopressin response.

Authors:  B S Dixon
Journal:  J Clin Invest       Date:  1994-06       Impact factor: 14.808

Review 6.  Long-range safety and protective benefits of angiotensin-converting enzyme inhibitors for hypertension. Do we need more clinical trials?

Authors:  M P Sambhi; H Gavras; J I Robertson; W M Smith
Journal:  West J Med       Date:  1993-03

Review 7.  Acute and chronic effects of angiotensin converting enzyme inhibitors on the essential hypertensive kidney.

Authors:  G P Reams; J H Bauer
Journal:  Cardiovasc Drugs Ther       Date:  1990-02       Impact factor: 3.727

8.  Effects of Hoe 140, a bradykinin B2-receptor antagonist, on renal function in conscious normotensive rats.

Authors:  P Madeddu; V Anania; P P Parpaglia; M P Demontis; M V Varoni; G Pisanu; C Troffa; G Tonolo; N Glorioso
Journal:  Br J Pharmacol       Date:  1992-06       Impact factor: 8.739

9.  Effects of bradykinin B2 receptor antagonism on the hypotensive effects of ACE inhibition.

Authors:  H Bouaziz; Y Joulin; M Safar; A Benetos
Journal:  Br J Pharmacol       Date:  1994-11       Impact factor: 8.739

Review 10.  The kallikrein-kinin system as a regulator of cardiovascular and renal function.

Authors:  Nour-Eddine Rhaleb; Xiao-Ping Yang; Oscar A Carretero
Journal:  Compr Physiol       Date:  2011-04       Impact factor: 9.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.